Botulism bacteria contamination found in All ByHeart baby formula, according to testing results.

Tests conducted on ByHeart infant formula, in connection with a botulism outbreak that has affected dozens of infants, have revealed potential contamination across the company’s product line. Laboratory analyses of 36 samples from three different production lots found that five samples contained Clostridium botulinum type A, the bacteria responsible for botulism, prompting concerns about the safety of all ByHeart formula products.

As of now, at least 31 infants across 15 states have fallen ill with botulism linked to ByHeart formula since the outbreak began in August 2025, according to reports from federal and state health officials. Furthermore, additional cases of botulism treatment were noted among infants who consumed the formula in prior months, extending back to November 2024. However, these earlier incidents are not officially counted in the current outbreak statistics.

The specific strain of bacteria detected can be unevenly distributed within powdered formulas, meaning not all babies who consume contaminated product will necessarily develop illness. Medical professionals caution that all infants under one year of age are particularly vulnerable to the effects of this bacteria.

In response to these alarming findings, ByHeart issued a nationwide recall of all its formula on November 11. Despite this action, state officials and representatives from the U.S. Food and Drug Administration (FDA) indicated that some recalled products remain available on store shelves, raising significant public health concerns.

Parents and caregivers are urged to stop using the potentially contaminated formula immediately and to carefully observe their children for symptoms of botulism. These symptoms can take up to 30 days to manifest and may include constipation, difficulty with feeding, drooping eyelids, a flat facial expression, and overall weakness in limbs and neck. Given that infant botulism can escalate into a medical emergency, immediate medical attention is critical.

Since the beginning of August, at least 107 infants have been treated for botulism using an intravenous medication known as BabyBIG. In a typical year, fewer than 200 infants are diagnosed with this serious illness.

Parents who purchased ByHeart products through the company’s official website after August 1 may be eligible for a full refund, broadening the company’s previous refund policy. For those who have experienced illness related to this outbreak, it is advised to reach out to an FDA consumer complaint coordinator or to complete an online MedWatch form to report the case and seek assistance.

As the situation develops, health officials continue to monitor the outbreak closely, prioritizing the safety and well-being of affected infants.

For more updates on this developing health issue and related public health information, stay informed through credible news sources. This situation highlights the critical importance of quality control in food safety, especially concerning products intended for vulnerable populations such as infants.

(Media News Source)